However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
Studies also suggest hope for TKI inhibitor combinations in patients with symptomatic brain metastases
Data from SECOMBIT provide useful insights to the optimal sequence of immune checkpoint inhibitor therapy and targeted treatment combinations for patients with BRAF-mutated, advanced melanoma
Immunotherapy was associated with a significant reduction in the risk of disease recurrence compared with placebo in patients with melanoma
The oncolytic herpes virotherapy does not show survival benefit in combination with pembrolizumab, but encouraging early data are reported with intratumoural injection of myeloid dendritic cells
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.